A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/21 (2006.01) A61K 38/19 (2006.01) A61K 39/395 (2006.01) C07K 16/28 (2006.01) C12N 15/13 (2006.01)
Patent
CA 2355607
This invention provides a composition for inhibiting HIV-1 infection comprising at least two compounds in synergistically effective amounts for inhibiting HIV-1 infection, wherein at least one of the compounds prevents the productive interaction between HIV-1 and an HIV-1 fusion co-receptor. This invention also provides a composition which inhibits fusion of HIV-1 or an HIV- 1 envelope glycoprotein+ cell to a target cell, comprising at least two compounds in synergistically effective amounts for inhibiting fusion of HIV-1 or an HIV-1 envelope glycoprotein+ cell to a target cell, wherein at least one of the compounds prevents the productive interaction between HIV-1 and an HIV- 1 fusion co-receptor. This invention also provides a method of treating a subject afflicted with HIV-1 which comprises administering to the subject an effective dose of said compositions. This invention also provides a method of preventing a subject from contracting HIV-1 which comprises administering to the subject an effective dose of said compositions. This invention also provides an anti-CCR5 monoclonal antibody selected from the group consisting of PA8, PA9, PA10, PA11, PA12, and PA14.
La présente invention concerne une composition permettant d'inhiber les infections dues au VIH-1, comprenant au moins deux composés en quantités suffisantes pour produire un effet synergique, inhibant les infections dues au VIH-1, et dans laquelle au moins un des composés empêche l'interaction productive entre le VIH-1 et le co-récepteur de fusion du VIH-1. Cette invention concerne également une composition inhibant la fusion du VIH-1 ou d'une cellule glycoprotéine d'enveloppe du VIH-1 avec une cellule cible, dans laquelle au moins un des composés empêche l'interaction productive entre le VIH-1 et le co-récepteur de fusion du VIH-1. L'invention concerne aussi un traitement convenant aux patients atteints par le VIH-1, consistant à administrer au patient une dose efficace desdites compositions. L'invention concerne en outre une méthode permettant de prévenir qu'un patient ne contracte le VIH-1, et consistant à lui administrer une dose efficace desdites compositions. Cette invention concerne enfin un anticorps monoclonal anti-CCR5, choisi dans le groupe composé de PA8, PA9, PA10, PA11, PA12 et PA14.
Maddon Paul J.
Olson William C.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Progenics Pharmaceuticals Inc.
LandOfFree
Anti-ccr5 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-ccr5 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-ccr5 antibody will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1889201